PMVP
PMVP
NASDAQ · Biotechnology

Pmv Pharmaceuticals Inc

$1.34
+0.10 (+8.06%)
As of Apr 1, 3:31 PM ET ·
Financial Highlights (FY 2025)
Revenue
14.44M
Net Income
-947,825
Gross Margin
62.5%
Profit Margin
-6.6%
Rev Growth
+21.5%
D/E Ratio
0.93
Revenue & Net Income
Margin Trends
FY 2025 FY 2024 FY 2023
Gross Margin 62.5% 62.5% 62.5%
Operating Margin -5.7% -5.5% -6.6%
Profit Margin -6.6% -5.7% -6.6%
Income Statement
FY 2025 FY 2024 FY 2023
Revenue 14.44M 13.53M 15.01M
Gross Profit 9.02M 8.45M 9.38M
Operating Income -826,095 -738,622 -997,716
Net Income -947,825 -765,390 -987,033
Gross Margin 62.5% 62.5% 62.5%
Operating Margin -5.7% -5.5% -6.6%
Profit Margin -6.6% -5.7% -6.6%
Rev Growth +21.5% +1.8% +6.7%
Balance Sheet
FY 2025 FY 2024 FY 2023
Total Debt 22.71M 20.12M 23.50M
Total Equity 24.32M 21.76M 23.84M
D/E Ratio 0.93 0.92 0.99
Cash Flow
FY 2025 FY 2024 FY 2023
EBITDA -1,267,375 -1,123,871 -1,333,015
Free Cash Flow -656,212 -624,188 -715,122